Name | 4SC-203 |
Description | 4SC-203 is a multi-kinase inhibitor with potential anti-tumor activity. 4SC-203 exhibits unique selectivity for Flt3, Flt3 mutants, Axl, Alk, Fak, VEGF-R2, and Trk receptors in the low nM range. |
In vitro | 4SC-203 exhibits unique selectivity in the low nM range for Flt3, Flt3 mutants, Axl, Alk, Fak, VEGF-R2, and Trk receptors.[1] |
In vivo | In preclinical studies, 4SC-203 demonstrated significant antitumor activity in in vivo models relevant to acute myeloid leukemia. In a first-in-human study in healthy volunteers, 4SC-203 was shown to be well tolerated across the concentration range studied and to have a favorable pharmacokinetic profile.[1] |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : Slightly soluble
|
Keywords | tumor | antineoplastic | Fms like tyrosine kinase 3 | Vascular endothelial growth factor receptor | FLT3 | 4SC203 | 4SC 203 | FLT3/STK1 | 4SC-203 | inhibit | VEGFR | Inhibitor | Cluster of differentiation antigen 135 | multikinase | CD135 |
Inhibitors Related | UNC2025 | Gilteritinib | Fedratinib | Nintedanib | Sunitinib | Sunitinib Malate | Sorafenib | Tandutinib | Pexidartinib | KW-2449 | Sorafenib tosylate | SGI-1776 |
Related Compound Libraries | Bioactive Compound Library | Tyrosine Kinase Inhibitor Library | Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | NO PAINS Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |